Uemura Masahito, Fujimura Yoshihiro, Matsuyama Tomomi, Matsumoto Masanori, Ishikawa Masatoshi, Ishizashi Hiromichi, Kato Seiji, Tsujimoto Tatsuhiro, Fujimoto Masao, Yoshiji Hitoshi, Morioka Chie, Fukui Hiroshi
Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, 634-8522, Japan.
Curr Drug Abuse Rev. 2008 Jun;1(2):188-96. doi: 10.2174/1874473710801020188.
Alcoholic hepatitis (AH) is a potentially life-threatening complication of alcohol abuse. The severe form of AH, severe alcoholic hepatitis (SAH), is characterized by multiorgan failure (MOF) with manifestations of acute hepatic failure and is associated with high morbidity and mortality. However, the pathogenesis of SAH in addition to AH remains to be elucidated. Recent advances showed that ADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13) is closely related to thrombotic thrombocytopenic purpura, a multiorgan disorder. Decreased activity of plasma ADAMTS13 (ADAMTS13:AC) leads to the accumulation of unusually large von Willebrand factor multimers (UL-VWFM) and subsequent platelet clumping and/or thrombi under high shear stress, resulting in microcirculatory disturbances. Immunological studies and in situ hybridization have indicated that ADAMTS13 is produced exclusively in hepatic stellate cells (HSCs). Plasma ADAMTS13:AC was extremely low in fatal SAH cases, and enhanced UL-VWFM production with deficient ADAMTS13:AC may contribute to the progression of MOF through microcirculatory disturbances in SAH and AH. Considering that ADAMTS13 is synthesized in HSCs and its substrate, UL-VWFM, is produced in transformed vascular endothelial cells, the imbalance between ADAMTS13:AC and VWF:Ag in AH patients might also involve sinusoidal microcirculatory disturbances and subsequent liver injury. It will be necessary to clarify the mechanism of the decrease in plasma ADAMTS13:AC in association with pro-inflammatory cytokinemia, an ADAMTS13 inhibitor and the production of ADAMTS13 in HSCs. The determination of ADAMTS13:AC and its substrate will give us new insights into the pathophysiology of acute alcoholic liver injury and help to elucidate additional therapeutic strategies for this disease.
酒精性肝炎(AH)是酒精滥用可能危及生命的并发症。严重酒精性肝炎(SAH)是AH的严重形式,其特征为多器官功能衰竭(MOF),伴有急性肝衰竭表现,且发病率和死亡率高。然而,SAH除AH之外的发病机制仍有待阐明。最近的研究进展表明,ADAMTS13(一种具有血小板反应蛋白基序的解整合素样金属蛋白酶13)与血栓性血小板减少性紫癜(一种多器官疾病)密切相关。血浆ADAMTS13活性(ADAMTS13:AC)降低会导致超大血管性血友病因子多聚体(UL-VWFM)异常蓄积,随后在高剪切应力下血小板聚集和/或形成血栓,导致微循环障碍。免疫学研究和原位杂交表明,ADAMTS13仅在肝星状细胞(HSC)中产生。在致命的SAH病例中,血浆ADAMTS13:AC极低,ADAMTS13:AC缺乏导致UL-VWFM生成增加,可能通过SAH和AH中的微循环障碍促进MOF进展。鉴于ADAMTS13在HSC中合成,其底物UL-VWFM在转化的血管内皮细胞中产生,AH患者中ADAMTS13:AC与血管性血友病因子抗原(VWF:Ag)之间的失衡可能也涉及肝血窦微循环障碍及随后的肝损伤。有必要阐明与促炎细胞因子血症、ADAMTS13抑制剂以及HSC中ADAMTS13产生相关的血浆ADAMTS13:AC降低的机制。测定ADAMTS13:AC及其底物将为急性酒精性肝损伤的病理生理学提供新的见解,并有助于阐明该疾病的其他治疗策略。